Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

AMPETOOR1


ABSTRACT: We hypothesised that in esophagogastric junction adenocarcinomas combining molecular predictive biomarkers with FDG-PET would optimise response prediction. Changes in FDG uptake in tumours meaured by PET scans after 14 days of chemotherapy define metabolic responders and non-responders. However while <5% of metabolic non-responders will go onto have a response to the full 9-12 week chemotherapy protocol providing a high negative predictive value for FDG-PET, the positive predictive value of metabolic response is more limited. Only 50% of those patients that have a metabolic response determined by FDG PET at day 14 will go on to subsequently have a response to the full 9-12 week chemotherapy protocol . We used global gene expression profiling to identify molecular biomarkers that when combined with FDG-PET would improve predictive accuracy, in particular we aimed to identify molecular biomarkers that could sub-classify FDG PET defined metabolic responders into those that did and did not subsequently go on to have a radiological response and hence clinical benefit from the full chemotherapy protocol. Patients with stage IB-IV esophagogastric junction adenocarcinomas(n=28) received platinum combination chemotherapy .FDG-PET CT scans were performed at baseline and day 14 and expression profiling (Affymetrix ST1.0 Exon Genechips) on baseline tumour biopsies. 14 patients were classified as FDG-PET metabolic responders and gene expression was analysed in these tumour specimens to determine differences between those that did subsequently go on to have a radiological response (n=10) or did not have a radiological response (n=4) to the full 9-12 week chemotherapy protocol. A tissue microarray(n=154 esophagogastric adenocarcinomas who underwent surgery+/-neoadjuvant chemotherapy)was used with immunohistochemistry for qualification of gene expression profiling results. Radiological response was assessed after 3or4 cycles of chemotherapy by RECISTv1.1.

ORGANISM(S): Homo sapiens

SUBMITTER: Russell Petty 

PROVIDER: E-MEXP-3730 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2011-11-01 | GSE21217 | GEO
2011-11-01 | E-GEOD-21217 | biostudies-arrayexpress
2022-04-05 | GSE164961 | GEO
2019-01-23 | GSE101491 | GEO
2020-03-18 | GSE135565 | GEO
2013-10-06 | E-GEOD-32877 | biostudies-arrayexpress
2024-04-03 | GSE235122 | GEO
| 2060203 | ecrin-mdr-crc
2021-09-08 | GSE150934 | GEO
2014-01-03 | E-GEOD-53781 | biostudies-arrayexpress